Abd El Fattah, N., Al Mokadem, S., Ghonemy, S. (2022). Brief Treatment Modalities of Alopecia Areata: Review Article. The Egyptian Journal of Hospital Medicine, 89(2), 6127-6131. doi: 10.21608/ejhm.2022.268103
Nermeen Mohamed Mahmoud Abd El Fattah; Sahar Mohamed Abd El Fattah Al Mokadem; Soheir Mohammed Ghonemy. "Brief Treatment Modalities of Alopecia Areata: Review Article". The Egyptian Journal of Hospital Medicine, 89, 2, 2022, 6127-6131. doi: 10.21608/ejhm.2022.268103
Abd El Fattah, N., Al Mokadem, S., Ghonemy, S. (2022). 'Brief Treatment Modalities of Alopecia Areata: Review Article', The Egyptian Journal of Hospital Medicine, 89(2), pp. 6127-6131. doi: 10.21608/ejhm.2022.268103
Abd El Fattah, N., Al Mokadem, S., Ghonemy, S. Brief Treatment Modalities of Alopecia Areata: Review Article. The Egyptian Journal of Hospital Medicine, 2022; 89(2): 6127-6131. doi: 10.21608/ejhm.2022.268103
Brief Treatment Modalities of Alopecia Areata: Review Article
Background: Hair loss on the scalp and/or body due to Alopecia Areata (AA) is a frequent autoimmune, inflammatory, nonscarring form of baldness. Hair loss can occur in a variety of patterns, from thinning in discrete areas to a complete loss of hair from follicle. All treatments of AA are considered off-label. While these therapies may help stimulate hair growth, they are not considered curative because they cannot alter the disease's normal progression. Age, general health, and the severity of hair loss all play a role in determining the best course of therapy. Objective: Assessment of current treatment modalities of alopecia areata. Methods: Treatment, and alopecia areata were all looked for in PubMed, Google scholar, and Science direct. References from relevant literature were also evaluated by the authors, but only the most recent or complete study from September 2007 to May 2021 was included. Due to the lack of sources for translation, documents in languages other than English have been ruled out. Papers that did not fall under the purview of major scientific investigations, such as unpublished manuscripts, oral presentations, conference abstracts, and dissertations, were omitted. Conclusion: Because of their low risk of adverse effects and simple administration, topical corticosteroids of varying strengths are often the first line of defense in the treatment of AA in children. In more advanced cases of AA, systemic therapies are performed. Most of these drugs work by modulating or suppressing the immune system.
View on SCiNiTO
Top